200 related articles for article (PubMed ID: 37497877)
21. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
22. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
23. Burden of illness and outcomes in second-line large B-cell lymphoma treatment: real-world analysis of Medicare beneficiaries.
Kilgore KM; Mohammadi I; Wong AC; Snider JT; Cheng P; Schroeder A; Patel AR
Future Oncol; 2021 Dec; 17(35):4837-4847. PubMed ID: 34645318
[TBL] [Abstract][Full Text] [Related]
24. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
[TBL] [Abstract][Full Text] [Related]
25. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Grønbæk K; Sundberg J; Pedersen LB; Ralfkiær E; Karjalainen-Lindsberg ML; Sundström C; Ehinger M; Geisler C; Jerkeman M
Blood; 2016 Oct; 128(14):1814-1820. PubMed ID: 27354719
[TBL] [Abstract][Full Text] [Related]
26. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
[TBL] [Abstract][Full Text] [Related]
27. Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis.
Yi JH; Kim SJ; Lee JO; Lee GW; Kwak JY; Eom HS; Jo JC; Choi YS; Oh SY; Kim WS
Anticancer Res; 2022 Dec; 42(12):6083-6089. PubMed ID: 36456154
[TBL] [Abstract][Full Text] [Related]
28. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
29. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
30. Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.
Patel DA; Wan F; Trinkaus K; Guy DG; Edwin N; Watkins M; Bartlett NL; Cashen A; Fehniger TA; Ghobadi A; Shah NM; Kahl BS
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):552-560. PubMed ID: 37183115
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
32. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Castellino A; Wang Y; Larson MC; Maurer MJ; Link BK; Farooq U; Feldman AL; Syrbu SI; Habermann TM; Paludo J; Inwards DJ; Witzig TE; Ansell SM; Allmer C; Slager SL; Cohen JB; Martin P; Cerhan JR; Nowakowski GS
Blood Adv; 2022 Feb; 6(4):1350-1360. PubMed ID: 34662895
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
Olszewski AJ; Butera JN; Reagan JL; Castillo JJ
Am J Hematol; 2020 Apr; 95(4):354-361. PubMed ID: 31849108
[TBL] [Abstract][Full Text] [Related]
34. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
35. Health Care Resource Utilization and Costs Among Medicare Beneficiaries Newly Diagnosed With Peripheral T-cell Lymphoma: A Retrospective Claims Analysis.
Shah A; Petrilla A; Rebeira M; Feliciano J; Lisano J; LeBlanc TW
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e1-e9. PubMed ID: 33184000
[TBL] [Abstract][Full Text] [Related]
36. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.
García-Noblejas A; Martínez Chamorro C; Navarro Matilla B; Da Silva Rodriguez C; González-Lopez TJ; Oña Navarrete R; Ramírez Sánchez MJ; Martínez Barranco P; Sánchez Blanco JJ; Nicolás C; Pérez R; Sánchez González B; Ruedas López AM; Domingo-Domenech E; Panizo C; Macia S; Fernández-Fonseca E; Cannata-Ortiz J; Arranz R
Ann Hematol; 2014 Sep; 93(9):1551-8. PubMed ID: 24782117
[TBL] [Abstract][Full Text] [Related]
37. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
38. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
39. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.
Goyal RK; Nagar SP; Kabadi SM; Le H; Davis KL; Kaye JA
Cancer Med; 2021 Apr; 10(8):2690-2702. PubMed ID: 33734606
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
